{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:16:03Z","timestamp":1794507363829,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40265-025-02272-z","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T18:19:37Z","timestamp":1767809977000},"page":"231-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials"],"prefix":"10.1007","volume":"86","author":[{"given":"Ibadete","family":"Byty\u00e7i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Henein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sefer","family":"Bytyqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mentor","family":"Shatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drilon","family":"Gashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endrit","family":"Dragusha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozafa","family":"Koliqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shpend","family":"Elezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2272_CR1","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44:2277\u201391.","journal-title":"Eur Heart J"},{"key":"2272_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478\u201390.","journal-title":"Eur Heart J"},{"key":"2272_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.574474","volume":"11","author":"M Vrablik","year":"2020","unstructured":"Vrablik M, Tich\u00fd L, Freiberger T, Blaha V, Satny M, Hubacek JA. Genetics of familial hypercholesterolemia: new insights. Front Genet. 2020;11:574474.","journal-title":"Front Genet"},{"key":"2272_CR4","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75:2553\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"2272_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","volume":"399","author":"TR Tromp","year":"2022","unstructured":"Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399:719\u201328.","journal-title":"Lancet"},{"key":"2272_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.atherosclerosissup.2014.07.004","volume":"15","author":"E Bruckert","year":"2014","unstructured":"Bruckert E. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society Consensus Statement. Atheroscler Suppl. 2014;15:26\u201332.","journal-title":"Atheroscler Suppl"},{"key":"2272_CR7","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013143.","journal-title":"Circulation"},{"key":"2272_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/MOL.0000000000000686","volume":"31","author":"AM B\u00e9langer","year":"2020","unstructured":"B\u00e9langer AM, Akioyamen L, Alothman L, Genest J. Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. Curr Opin Lipidol. 2020;31:176\u201381.","journal-title":"Curr Opin Lipidol"},{"key":"2272_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","volume":"255","author":"M France","year":"2016","unstructured":"France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016;255:128\u201339.","journal-title":"Atherosclerosis"},{"key":"2272_CR10","first-page":"1553","volume":"34","author":"LR Brunham","year":"2018","unstructured":"Brunham LR, Ruel I, Aljenedil S, Riviere JB, Baass A, Tu JV, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. Can J Cardiol. 2018;34:1553\u201363.","journal-title":"Can J Cardiol"},{"key":"2272_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","volume":"277","author":"FJ Raal","year":"2018","unstructured":"Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483\u201392.","journal-title":"Atherosclerosis"},{"key":"2272_CR12","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37:3588\u201395.","journal-title":"Eur Heart J"},{"key":"2272_CR13","volume":"2017","author":"NG Seidah","year":"2017","unstructured":"Seidah NG. The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob Cardiol Sci Pract. 2017;2017:e201702.","journal-title":"Glob Cardiol Sci Pract"},{"key":"2272_CR14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","volume":"34","author":"L D\u2019Erasmo","year":"2017","unstructured":"D\u2019Erasmo L, Cefalu AB, Noto D, Giammanco A, Averna M, Pintus P, et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther. 2017;34:1200\u201310.","journal-title":"Adv Ther"},{"key":"2272_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14656566.2017.1340941","volume":"18","author":"AJ Berberich","year":"2017","unstructured":"Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18:1261\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"2272_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"FJ Raal","year":"2017","unstructured":"Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5:280\u201390.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2272_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","volume":"38","author":"A Thedrez","year":"2018","unstructured":"Thedrez A, Blom DJ, Ramin-Mangata S, et al. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab. Arterioscler Thromb Vasc Biol. 2018;38:592\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2272_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"2272_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.envint.2018.07.015","volume":"121","author":"RL Morgan","year":"2018","unstructured":"Morgan RL, Whaley P, Thayer KA, Sch\u00fcnemann HJ. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int. 2018;121(1):1027\u201331.","journal-title":"Environ Int"},{"key":"2272_CR20","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] The Cochrane Collaboration. 2011. www.handbook.cochrane.org. Accessed 2 Dec 2024."},{"key":"2272_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"2272_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"2272_CR23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","volume":"128","author":"EA Stein","year":"2013","unstructured":"Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113\u201320.","journal-title":"Circulation"},{"key":"2272_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341\u201350.","journal-title":"Lancet"},{"key":"2272_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","volume":"76","author":"DJ Blom","year":"2020","unstructured":"Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH Trial. J Am Coll Cardiol. 2020;76:131\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2272_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","volume":"75","author":"RD Santos","year":"2020","unstructured":"Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, et al. long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(6):565\u201374.","journal-title":"J Am Coll Cardiol"},{"key":"2272_CR27","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/ATVBAHA.122.317793","volume":"42","author":"E Bruckert","year":"2022","unstructured":"Bruckert E, Caprio S, Wiegman A, Charng MJ, Z\u00e1rate-Morales CA, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. Arterioscler Thromb Vasc Biol. 2022;42:1447\u201357.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2272_CR28","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jacl.2021.10.003","volume":"15","author":"S Bansal","year":"2021","unstructured":"Bansal S, Ruzza A, Sawhney J, Kulkarni G, Iyengar S, Mehta V, et al. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021;15:814\u201321.","journal-title":"J Clin Lipidol"},{"key":"2272_CR29","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/ATVBAHA.119.313051","volume":"39","author":"P Banerjee","year":"2019","unstructured":"Banerjee P, Chan KC, Tarabocchia M, Benito-Vicente A, Alves AC, Uribe KB, et al. Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. Arterioscler Thromb Vasc Biol. 2019;39:2248\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2272_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100648","volume":"2","author":"FJ Raal","year":"2023","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia. JACC Adv. 2023;2(9):100648.","journal-title":"JACC Adv"},{"issue":"24","key":"2272_CR31","first-page":"00189","volume":"S1933\u20132874","author":"C Stefanutti","year":"2024","unstructured":"Stefanutti C, Chan DC, Dip GZ, Watts GF. Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and not treating with lipoprotein apheresis. J Clin Lipidol. 2024;S1933\u20132874(24):00189\u201392.","journal-title":"J Clin Lipidol"},{"key":"2272_CR32","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","volume":"45","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, et al. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024;45:2422\u201334.","journal-title":"Eur Heart J"},{"issue":"6","key":"2272_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","volume":"44","author":"S B\u00e9liard","year":"2024","unstructured":"B\u00e9liard S, Saheb S, Litzler-Renault S, Vimont A, Valero R, Bruckert \u00c9, et al. Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2024;44(6):1447\u201354.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2272_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149:343\u201353.","journal-title":"Circulation"},{"key":"2272_CR35","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"2272_CR36","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1093\/eurjpc\/zwae144","volume":"31","author":"J Gu","year":"2024","unstructured":"Gu J, Gupta RN, Cheng HK, Xu Y, Raal FJ. Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary. Eur J Prev Cardiol. 2024;31:1833\u201349.","journal-title":"Eur J Prev Cardiol"},{"key":"2272_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, O\u2019Donnell CJ, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593:429\u201334.","journal-title":"Nature"},{"key":"2272_CR38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00129784-200404040-00002","volume":"4","author":"MH Moghadasian","year":"2004","unstructured":"Moghadasian MH, McManus BM, Frohlich J, Hegele RA, Mancini GB, Hill JS, et al. Homozygous familial hypercholesterolemia: diagnosis, clinical manifestations, and management. Am J Cardiovasc Drugs. 2004;4:211\u201321.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2272_CR39","first-page":"105","volume":"10","author":"I Ruel","year":"2016","unstructured":"Ruel I, Aljenedil S, Sadri I, Paquette M, Couture P, Genest J, et al. Aortic valve disease in homozygous familial hypercholesterolemia. J Clin Lipidol. 2016;10:105\u201312.","journal-title":"J Clin Lipidol"},{"key":"2272_CR40","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2015.03.014","volume":"240","author":"C Stefanutti","year":"2015","unstructured":"Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron HD, Marais AD, et al. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia\u2014a post-hoc analysis of a phase 3, single-arm, open-label trial. Atherosclerosis. 2015;240:408\u201314.","journal-title":"Atherosclerosis"},{"key":"2272_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40256-021-00497-3","volume":"22","author":"M Rossi","year":"2022","unstructured":"Rossi M, Fabris E, Barbisan D, Massa L, Sinagra G. Lipid-lowering drug therapy: critical approach for implementation in clinical practice. Am J Cardiovasc Drugs. 2022;22:141\u201355.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2272_CR42","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","volume":"383","author":"RD Santos","year":"2020","unstructured":"Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383:1317\u201327.","journal-title":"N Engl J Med"},{"key":"2272_CR43","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","volume":"10","author":"R Alonso","year":"2016","unstructured":"Alonso R, Diaz-Diaz JL, Arrieta F, et al. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry. J Clin Lipidol. 2016;10:953\u201361.","journal-title":"J Clin Lipidol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02272-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:58:03Z","timestamp":1769849883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02272-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02272-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Speaker\u2019s bureau: MB: Amgen, Adamed, Daiichi Sankyo, KRKA, MSD, Polpharma, Mylan\/Viatris, Novartis, Novo-Nordisk, Pfizer, Sanofi, Teva, Zentiva; consultant to Adamed, Amgen, Daiichi Sankyo, Lilly, MSD, New Amsterdam, Novartis, Novo-Nordisk, Sanofi, Teva; Grants from Amgen, Daiichi Sankyo, Viatris, Sanofi, and Teva. All other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article (and its supplementary information files).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"I.B. and S.E.: conceptualization, study design, methodology and project administration; I.B., S.B., D.G., M.S., E.D.: data analysis and writing the first draft of manuscript. M.B., M.Y.H., I.B., R.K., A.V.H., S.E.: review manuscript. I.B., M.B., A.V.H. revised the manuscript and prepared the final version. All authors have read and agreed to the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}